Infectious causes of cancer

Stratify Genomics partners with PWNHealth to deliver groundbreaking service to online customers

Retrieved on: 
Monday, November 25, 2019

Stratify has teamed up with PWNHealth to provide clinical oversight and patient support through the Stratify online portal.

Key Points: 
  • Stratify has teamed up with PWNHealth to provide clinical oversight and patient support through the Stratify online portal.
  • Through this online tool, Stratify enables men to easily order the Prompt PGS test online and receive guidance from clinicians recommending how often they should receive Prostate Specific Antigen (PSA) screening based on their individual results.
  • "Stratify Genomics is proud to team up with PWNHealth to provide minimally-invasive, low-cost tests for prostate cancer risk and potentially save lives through our groundbreaking online telemedicine partnership," said Martyn Gross, President of Stratify Genomics.
  • This easy-to-use cheek swab test is now readily available to men thanks to our online partnership with PWN."

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

Retrieved on: 
Monday, November 25, 2019

Neisseria gonorrhoeae are highly adept at avoiding the action of antibiotics that are meant to kill them.

Key Points: 
  • Neisseria gonorrhoeae are highly adept at avoiding the action of antibiotics that are meant to kill them.
  • CARB-X is investing up to $500 million between 2016-2021 to support the development of new antibiotics, rapid diagnostics, vaccines and other life-saving products.
  • CARB-X is investing up to $500 million between 2016 and 2021 to support innovative antibiotics, vaccines, rapid diagnostics, and other life-saving products.
  • VenatoRx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections.

Global In-vitro Colorectal Cancer Screening Tests Market 2019-2023 | Evolving Opportunities with Abbott & Danaher | Technavio

Retrieved on: 
Friday, November 22, 2019
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191122005412/en/
    Technavio has announced its latest market research report titled global in-vitro colorectal cancer screening tests market 2019-2023.
  • (Graphic: Business Wire)
    Read the 127-page research report with TOC on "In-vitro Colorectal Cancer Screening Tests Market Analysis Report by End-user (Hospitals, Clinical diagnostic laboratories, and Others) and Geography (Americas, APAC, and EMEA) 2019-2023".
  • Also, the increased rate of product approval is anticipated to further boost the growth of the in-vitro colorectal cancer screening tests market.
  • Mars Bleu was launched by NOVIGENIX as a national colorectal cancer awareness campaign and was dedicated to raising awareness about screening and preventing colorectal cancer in many countries.

Stupid Strong 5th Anniversary Event Raises Over $285,000 To Support Gastric Cancer Research

Retrieved on: 
Friday, November 22, 2019

With over 300 guests, more than $285,000 was raised to fund research and support stomach cancer patients and families worldwide.

Key Points: 
  • With over 300 guests, more than $285,000 was raised to fund research and support stomach cancer patients and families worldwide.
  • "Stupid Strong has awarded over $400,000 to fund gastric cancer research to date," said Vice-President (and event co-chair) Ashley Elmore.
  • Earlier this year, Stupid Strong officially awarded The University of Texas MD Anderson Cancer Center its newly formed Seed Research Grant.
  • Stupid Strong exists for the purpose of makingthe cure for gastric cancer a reality.

Global $5.79Bn Human Papilloma Virus (HPV) Market Outlook and Forecast 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 22, 2019

The global Human Papilloma Virus (HPV) Vaccine market is expected to grow at a CAGR of 9.79% during the forecast period to reach a total market size of US$5.79 billion by 2024, increasing from US$3.305 billion in 2018.

Key Points: 
  • The global Human Papilloma Virus (HPV) Vaccine market is expected to grow at a CAGR of 9.79% during the forecast period to reach a total market size of US$5.79 billion by 2024, increasing from US$3.305 billion in 2018.
  • Human Papilloma Virus (HPV) Vaccine protects from certain types of Human Papilloma Viruses that can lead to cancer or genital warts.
  • The market for global Human Papilloma Virus (HPV) Vaccine is augmented by increasing number of Cervical Cancer cases worldwide.
  • Major players in the human papilloma virus (HPV) Vaccine market have been covered along with their relative competitive position and strategies.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Retrieved on: 
Thursday, November 21, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.
  • Fiscal Fourth Quarter and Year Ended September 30, 2019 Financial Results
    Total revenue of $51.3 million for the three months ended September 30, 2019 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET.
  • The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as reported by AbbVie.
  • Enanta plans to issue its fiscal first quarter 2020 financial results press release, and hold a conference call regarding those results, on February 6, 2020.

Brii Biosciences Expands Infectious Disease Pipeline

Retrieved on: 
Thursday, November 21, 2019

Brii Bio began with a major effort in infectious diseases because the need is great in China and the threat is global, said Zhi Hong, Ph.D., co-founder and CEO of Brii Bio.

Key Points: 
  • Brii Bio began with a major effort in infectious diseases because the need is great in China and the threat is global, said Zhi Hong, Ph.D., co-founder and CEO of Brii Bio.
  • Brii Bio is joining this effort with a focus on China, where resistance is more prevalent.
  • Brii Bios initial strategic focus takes aim at some of the most serious infectious diseases facing China and world populations today.
  • In addition to novel antibacterial agents, Brii Bio is also progressing a pipeline of assets focused on the functional cure for hepatitis B virus (HBV) infection.

Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH

Retrieved on: 
Thursday, November 21, 2019

Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Companys website at www.altimmune.com .

Key Points: 
  • Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Companys website at www.altimmune.com .
  • Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies.
  • Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX and NasoShield).
  • The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time.

Hope4Cancer™ Treatment Centers To Launch 'Eight Days' The First Reality Show About Alternative Ways To Fight Cancer

Retrieved on: 
Wednesday, November 20, 2019

From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms.

Key Points: 
  • From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms.
  • The five patients highlighted in the series include Kate Malvenan, diagnosed with Stage 4 Lung Cancer.
  • The 39-year old solo mother from Australia's Gold Coast is determined to beat cancer for her 3-year-old daughter, Annabelle.
  • Eight Days was born out of a desire to help, embarking on season two with Hope4Cancer Treatment Centers.

HOOKIPA Pharma Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, November 12, 2019

NEW YORK and VIENNA, Austria, Nov. 12, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2019 and provides a corporate update.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 12, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2019 and provides a corporate update.
  • In the third quarter, HOOKIPA has made significant progress toward achieving its corporate objectives.
  • HOOKIPA expects safety and immunogenicity data in the first half of 2020 from the first cohorts enrolled.
  • HOOKIPA reaffirms its plan to initiate a Phase1/2 clinical trial of HB-201 in patients with treatment-refractory HPV16+ cancers before the end of the year.